Explore the latest advances in alopecia areata treatment, including FDA-approved JAK inhibitors and promising topical ...

Long term data were announced from a phase 3 trial evaluating baricitinib in adolescents aged 12 to less than 18 years with severe alopecia areata.

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

"Lilly and Incyte to seek approval of alopecia JAK inhibitor in children" was originally created and published by Clinical ...

More than half of adolescents treated with baricitinib achieved complete or near-complete scalp hair regrowth at 1 year, with ...

Scientists at Taiwan University have discovered a potential baldness cure using fat cell serum that could regrow hair in just ...

Fifty-four percent of patients ages 12 to 18 with severe alopecia noticed hair regrowth when given 4-mg of Olumiant (oral baricitinib), according to results of a study presented this week at the 2025 ...

Intervention/Treatment: The study tests two doses of ritlecitinib, 50 mg and 100 mg, administered orally once daily. Ritlecitinib is designed to treat alopecia areata by potentially reducing hair loss ...

From fish DNA injections to LED helmets, our writer tests the latest hair-loss treatments in search of thicker hair and ...

Western Mass News spoke to a woman whose been struggling with hair loss since she was a teen, and the doctor who’s been helping her grow it back.

The alopecia areata market is projected to grow significantly in the seven major markets, driven by an expanding pipeline with diverse mechanisms of action, including JAK inhibitors and IL-2 T ...

Forte Biosciences Inc. (($FBRX)) announced an update on their ongoing clinical study. Forte Biosciences Inc. is conducting a study titled ‘A ...